Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia
Aclipse and its collaborators have Keynote and Industry Day presentations at the 7 th Annual ALS One Research Symposium Poster presentation at the 35 th International Symposium on ALS/Motor Neurone Disease M102, an NRF2 and HSF1 activator, to initiate Phase 1 human trials in Q1 2025 KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has been selected for presentations at the premier amyotrophic lateral
